Lymphopenia Assessment in Stage III Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With Proton or Photon Radiation Therapy
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Date
2021-11Journal
International Journal of Radiation Oncology - Biology - PhysicsPublisher
ElsevierType
Abstract
Metadata
Show full item recordAbstract
The degree of lymphopenia has been linked with negative impact on outcomes in patients undergoing radiation therapy (RT) for stage III non-small cell lung cancer (NSCLC). Proton therapy, by virtue of reducing integral dose, can possibly help mitigate risk of lymphopenia as demonstrated in patients with glioblastoma and esophageal cancer. This study sought to analyze the effects of intensity modulated proton therapy (IMPT) in limiting degree of lymphopenia in patients with stage III NSCLC when compared to those treated with photon-based volumetric-modulated arc therapy (VMAT).Rights/Terms
Copyright © 2021 Published by Elsevier Inc.Identifier to cite or link to this item
http://hdl.handle.net/10713/18473ae974a485f413a2113503eed53cd6c53
10.1016/j.ijrobp.2021.07.1263